Details of the Drug

General Information of Drug (ID: DMSZQAK)

Drug Name
Amphetamine
Synonyms Amphetamine (tamper and abuse-resistant, Bio-MD/MPAR, ADHD); Amphetamine (tamper and abuse-resistant, Bio-MD/MPAR, ADHD), PharmacoFore; PF-08 (Bio-MD/MPAR/prodrug/oral, ADHD), PharmacoFore
Indication
Disease Entry ICD 11 Status REF
Attention deficit hyperactivity disorder 6A05.Z Approved [1]
Drug Type
Small molecular drug
Structure
3D MOL is unavailable 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 135.21
Topological Polar Surface Area (xlogp) 1.8
Rotatable Bond Count (rotbonds) 2
Hydrogen Bond Donor Count (hbonddonor) 1
Hydrogen Bond Acceptor Count (hbondacc) 1
ADMET Property
Bioavailability
The bioavailability of drug is 72% [2]
Clearance
The drug present in the plasma can be removed from the body at the rate of 9.7 mL/min/kg [3]
Elimination
The elimination of amphetamine is mainly via the urine from which about 40% of the excreted dose is found as unchanged amphetamine [4]
Half-life
The concentration or amount of drug in body reduced by one-half in 9 - 11 hours [4]
Metabolism
The drug is metabolized via the liver [5]
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 7.39587 micromolar/kg/day [6]
Unbound Fraction
The unbound fraction of drug in plasma is 0.8% [3]
Vd
The volume of distribution (Vd) of drug is 4 L/kg [4]
Water Solubility
The ability of drug to dissolve in water is measured as 30 mg/mL [7]
Chemical Identifiers
Formula
C9H13N
IUPAC Name
1-phenylpropan-2-amine
Canonical SMILES
CC(CC1=CC=CC=C1)N
InChI
InChI=1S/C9H13N/c1-8(10)7-9-5-3-2-4-6-9/h2-6,8H,7,10H2,1H3
InChIKey
KWTSXDURSIMDCE-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
3007
ChEBI ID
CHEBI:2679
CAS Number
300-62-9
DrugBank ID
DB00182
TTD ID
D05BMG
VARIDT ID
DR00084
INTEDE ID
DR0106
ACDINA ID
D00036

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Trace amine-associated receptor-1 (TAAR1) TTIU98M TAAR1_HUMAN Modulator [8], [9], [10], [11], [1]

Drug Transporter (DTP)
DTP Name DTP ID UniProt ID MOA REF
Sodium-dependent dopamine transporter (SLC6A3) DT3BA8L SC6A3_HUMAN Substrate [12]
Sodium-dependent noradrenaline transporter (SLC6A2) DT9JBVI SC6A2_HUMAN Substrate [12]
Organic cation/carnitine transporter 2 (SLC22A5) DT3HUVD S22A5_HUMAN Substrate [13]
Organic cation transporter 3 (SLC22A3) DT6201N S22A3_HUMAN Substrate [14]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 2D6 (CYP2D6)
Main DME 		DECB0K3 CP2D6_HUMAN Substrate [15]
Tyramine oxidase (tynA) DEB3TNR AMO_ECOLI Substrate [16]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Attention deficit hyperactivity disorder
ICD Disease Classification 6A05.Z
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Trace amine-associated receptor-1 (TAAR1) DTT TAAR1 6.12E-01 -0.01 -0.06
Sodium-dependent noradrenaline transporter (SLC6A2) DTP NET 7.05E-01 7.02E-03 6.74E-02
Organic cation transporter 3 (SLC22A3) DTP SLC22A3 3.72E-01 5.29E-02 3.62E-01
Organic cation/carnitine transporter 2 (SLC22A5) DTP OCTN2 1.13E-01 -5.69E-03 -4.16E-02
Sodium-dependent dopamine transporter (SLC6A3) DTP DAT1 4.17E-01 4.04E-03 2.45E-02
Cytochrome P450 2D6 (CYP2D6) DME CYP2D6 5.64E-01 2.36E-02 1.75E-01
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Amphetamine (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Sodium bicarbonate DMMU6BJ Moderate as urine pH determines the ionization state of weakly acidic or weakly alkaline drugs. Amphetamine caused by Sodium bicarbonate mediated altered urine pH. Acidosis [5C73] [53]
Tromethamine DMOBLGK Moderate as urine pH determines the ionization state of weakly acidic or weakly alkaline drugs. Amphetamine caused by Tromethamine mediated altered urine pH. Acidosis [5C73] [53]
Methylene blue DMJAPE7 Major Increased risk of hyperpyrexia by the combination of Amphetamine and Methylene blue. Acquired methaemoglobinaemia [3A93] [54]
Ranolazine DM0C9IL Moderate Decreased metabolism of Amphetamine caused by Ranolazine mediated inhibition of CYP450 enzyme. Angina pectoris [BA40] [55]
Dronedarone DMA8FS5 Moderate Decreased metabolism of Amphetamine caused by Dronedarone mediated inhibition of CYP450 enzyme. Angina pectoris [BA40] [56]
Clobazam - Lundbeck DMW1OQ0 Moderate Decreased metabolism of Amphetamine caused by Clobazam - Lundbeck mediated inhibition of CYP450 enzyme. Anxiety disorder [6B00-6B0Z] [57]
Promazine DMZAL7W Moderate Antagonize the effect of Amphetamine when combined with Promazine. Appearance/behaviour symptom [MB23] [58]
Droxidopa DM5YF4M Moderate Additive hypertensive effects by the combination of Amphetamine and Droxidopa. Autonomic nervous system disorder [8D87] [59]
Linezolid DMGFPU2 Major Increased risk of hyperpyrexia by the combination of Amphetamine and Linezolid. Bacterial infection [1A00-1C4Z] [54]
Rabeprazole DMMZXIW Moderate Decreased absorption of Amphetamine due to altered gastric pH caused by Rabeprazole. Bacterial infection [1A00-1C4Z] [60]
Selegiline DM6034S Major Increased risk of hyperpyrexia by the combination of Amphetamine and Selegiline. Depression [6A70-6A7Z] [54]
Isocarboxazid DMAF1NB Major Increased risk of hyperpyrexia by the combination of Amphetamine and Isocarboxazid. Depression [6A70-6A7Z] [54]
Tranylcypromine DMGB5RE Major Increased risk of hyperpyrexia by the combination of Amphetamine and Tranylcypromine. Depression [6A70-6A7Z] [54]
Phenelzine DMHIDUE Major Increased risk of hyperpyrexia by the combination of Amphetamine and Phenelzine. Depression [6A70-6A7Z] [54]
Esketamine DMVU687 Major Additive hypertensive effects by the combination of Amphetamine and Esketamine. Depression [6A70-6A7Z] [61]
SODIUM CITRATE DMHPD2Y Moderate as urine pH determines the ionization state of weakly acidic or weakly alkaline drugs. Amphetamine caused by SODIUM CITRATE mediated altered urine pH. Discovery agent [N.A.] [53]
Mirabegron DMS1GYT Moderate Decreased metabolism of Amphetamine caused by Mirabegron mediated inhibition of CYP450 enzyme. Functional bladder disorder [GC50] [62]
Darifenacin DMWXLYZ Moderate Decreased metabolism of Amphetamine caused by Darifenacin mediated inhibition of CYP450 enzyme. Functional bladder disorder [GC50] [63]
Terbinafine DMI6HUW Moderate Decreased metabolism of Amphetamine caused by Terbinafine mediated inhibition of CYP450 enzyme. Fungal infection [1F29-1F2F] [64]
Omeprazole DM471KJ Moderate Decreased absorption of Amphetamine due to altered gastric pH caused by Omeprazole. Gastro-oesophageal reflux disease [DA22] [60]
Procarbazine DMIK367 Major Increased risk of hyperpyrexia by the combination of Amphetamine and Procarbazine. Hodgkin lymphoma [2B30] [54]
Delavirdine DM3NF5G Moderate Decreased metabolism of Amphetamine caused by Delavirdine mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [65]
Cobicistat DM6L4H2 Moderate Decreased metabolism of Amphetamine caused by Cobicistat mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [66]
Didanosine DMI2QPE Moderate Decreased absorption of Amphetamine due to altered gastric pH caused by Didanosine. Human immunodeficiency virus disease [1C60-1C62] [67]
Ritonavir DMU764S Moderate Decreased metabolism of Amphetamine caused by Ritonavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [68]
Cinacalcet DMCX0K3 Moderate Decreased metabolism of Amphetamine caused by Cinacalcet mediated inhibition of CYP450 enzyme. Hyper-parathyroidism [5A51] [61]
Sodium acetate anhydrous DMH21E0 Moderate as urine pH determines the ionization state of weakly acidic or weakly alkaline drugs. Amphetamine caused by Sodium acetate anhydrous mediated altered urine pH. Hypo-osmolality/hyponatraemia [5C72] [53]
Givosiran DM5PFIJ Moderate Decreased metabolism of Amphetamine caused by Givosiran mediated inhibition of CYP450 enzyme. Inborn porphyrin/heme metabolism error [5C58] [69]
Propiomazine DMKY8V1 Moderate Antagonize the effect of Amphetamine when combined with Propiomazine. Insomnia [7A00-7A0Z] [58]
Polyethylene glycol DM4I1JP Moderate Increased risk of lowers seizure threshold by the combination of Amphetamine and Polyethylene glycol. Irritable bowel syndrome [DD91] [70]
Glycerol phenylbutyrate DMDGRQO Moderate Decreased metabolism of Amphetamine caused by Glycerol phenylbutyrate mediated inhibition of CYP450 enzyme. Liver disease [DB90-DB9Z] [71]
Dacomitinib DMOH8VY Moderate Decreased metabolism of Amphetamine caused by Dacomitinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [72]
Vemurafenib DM62UG5 Moderate Decreased metabolism of Amphetamine caused by Vemurafenib mediated inhibition of CYP450 enzyme. Melanoma [2C30] [73]
Ozanimod DMT6AM2 Major Increased risk of hyperpyrexia by the combination of Amphetamine and Ozanimod. Multiple sclerosis [8A40] [54]
Nilotinib DM7HXWT Moderate Decreased metabolism of Amphetamine caused by Nilotinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [74]
Imatinib DM7RJXL Moderate Decreased metabolism of Amphetamine caused by Imatinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [75]
Prochlorperazine DM53SRA Moderate Antagonize the effect of Amphetamine when combined with Prochlorperazine. Nausea/vomiting [MD90] [58]
Promethazine DM6I5GR Moderate Antagonize the effect of Amphetamine when combined with Promethazine. Nausea/vomiting [MD90] [58]
Rolapitant DM8XP26 Moderate Decreased metabolism of Amphetamine caused by Rolapitant mediated inhibition of CYP450 enzyme. Nausea/vomiting [MD90] [76]
Thiethylperazine DMU3IET Moderate Antagonize the effect of Amphetamine when combined with Thiethylperazine. Nausea/vomiting [MD90] [58]
Bupropion DM5PCS7 Major Increased risk of lowers seizure threshold by the combination of Amphetamine and Bupropion. Nicotine use disorder [6C4A] [77]
Lorcaserin DMG6OYJ Moderate Decreased metabolism of Amphetamine caused by Lorcaserin mediated inhibition of CYP450 enzyme. Obesity [5B80-5B81] [78]
Tramadol DMRQD04 Major Increased risk of lowers seizure threshold by the combination of Amphetamine and Tramadol. Pain [MG30-MG3Z] [79]
Safinamide DM0YWJC Major Additive hypertensive effects by the combination of Amphetamine and Safinamide. Parkinsonism [8A00] [54]
Rasagiline DM3WKQ4 Moderate Additive hypertensive effects by the combination of Amphetamine and Rasagiline. Parkinsonism [8A00] [54]
Lindane DMB8CNL Moderate Increased risk of lowers seizure threshold by the combination of Amphetamine and Lindane. Pediculosis [1G00] [80]
Esomeprazole DM7BN0X Moderate Decreased absorption of Amphetamine due to altered gastric pH caused by Esomeprazole. Peptic ulcer [DA61] [60]
ABIRATERONE DM8V75C Moderate Decreased metabolism of Amphetamine caused by ABIRATERONE mediated inhibition of CYP450 enzyme. Prostate cancer [2C82] [81]
Levomepromazine DMIKFEL Moderate Antagonize the effect of Amphetamine when combined with Levomepromazine. Psychotic disorder [6A20-6A25] [58]
Triflupromazine DMKFQJP Moderate Antagonize the effect of Amphetamine when combined with Triflupromazine. Psychotic disorder [6A20-6A25] [58]
Celecoxib DM6LOQU Moderate Decreased metabolism of Amphetamine caused by Celecoxib mediated inhibition of CYP450 enzyme. Rheumatoid arthritis [FA20] [82]
Mesoridazine DM2ZGAN Moderate Antagonize the effect of Amphetamine when combined with Mesoridazine. Schizophrenia [6A20] [58]
Thioridazine DM35M8J Moderate Antagonize the effect of Amphetamine when combined with Thioridazine. Schizophrenia [6A20] [58]
Haloperidol DM96SE0 Moderate Antagonize the effect of Amphetamine when combined with Haloperidol. Schizophrenia [6A20] [58]
Perphenazine DMA4MRX Moderate Antagonize the effect of Amphetamine when combined with Perphenazine. Schizophrenia [6A20] [58]
Chlorpromazine DMBGZI3 Moderate Antagonize the effect of Amphetamine when combined with Chlorpromazine. Schizophrenia [6A20] [58]
Trifluoperazine DMKBYWI Moderate Antagonize the effect of Amphetamine when combined with Trifluoperazine. Schizophrenia [6A20] [58]
Methdilazine DMAUHQX Moderate Antagonize the effect of Amphetamine when combined with Methdilazine. Vasomotor/allergic rhinitis [CA08] [58]
Trimeprazine DMEMV9D Moderate Antagonize the effect of Amphetamine when combined with Trimeprazine. Vasomotor/allergic rhinitis [CA08] [83]
⏷ Show the Full List of 59 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
FD&C blue no. 1 E00263 19700 Colorant
Mannitol E00103 6251 Diluent; Flavoring agent; Lyophilization aid; Plasticizing agent; Tonicity agent
Stearic acid E00079 5281 Emulsifying agent; Solubilizing agent; Viscosity-controlling agent; lubricant
Sucralose E00370 71485 Flavoring agent
Citric acid monohydrate E00271 22230 Acidulant; Antioxidant; Buffering agent; Complexing agent; Flavoring agent
Crospovidone E00626 Not Available Disintegrant
Fructose E00447 2723872 Flavoring agent
Magnesium stearate E00208 11177 lubricant
Silicon dioxide E00670 Not Available Anticaking agent; Opacifying agent; Viscosity-controlling agent
Triethyl citrate E00128 6506 Plasticizing agent; Solvent
⏷ Show the Full List of 10 Pharmaceutical Excipients of This Drug
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Amphetamine 12.5 mg tablet 12.5 mg 24 HR Extended Release Oral Tablet Oral
Amphetamine 15.7 mg tablet 15.7 mg 24 HR Extended Release Oral Tablet Oral
Amphetamine 18.8 mg tablet 18.8 mg 24 HR Extended Release Oral Tablet Oral
Amphetamine 3.1 mg tablet 3.1 mg 24 HR Extended Release Oral Tablet Oral
Amphetamine 6.3 mg tablet 6.3 mg 24 HR Extended Release Oral Tablet Oral
Amphetamine 9.4 mg tablet 9.4 mg 24 HR Extended Release Oral Tablet Oral
Amphetamine 10 mg tablet 10 mg Oral Tablet Oral
Amphetamine 5 mg tablet 5 mg Oral Tablet Oral
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
2 Cruz MP: Vilazodone HCl (Viibryd): A Serotonin Partial Agonist and Reuptake Inhibitor For the Treatment of Major Depressive Disorder. P T. 2012 Jan;37(1):28-31.
3 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
4 Clinical pharmacokinetics of amfetamine and related substances: monitoring in conventional and non-conventional matrices. Clin Pharmacokinet. 2004;43(3):157-85. doi: 10.2165/00003088-200443030-00002.
5 D-amphetamine sulfate information
6 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
7 BDDCS applied to over 900 drugs
8 Methamphetamine and HIV-1-induced neurotoxicity: role of trace amine associated receptor 1 cAMP signaling in astrocytes. Neuropharmacology. 2014 Oct;85:499-507.
9 Alpha-1B adrenergic receptor knockout mice are protected against methamphetamine toxicity. J Neurochem. 2003 Jul;86(2):413-21.
10 Involvement of the alpha(1D)-adrenergic receptor in methamphetamine-induced hyperthermia and neurotoxicity in rats. Neurotox Res. 2013 Aug;24(2):130-8.
11 Methamphetamine increases the hippocampal alpha(2A)-adrenergic receptor and Galpha(o) in mice. Neurosci Lett. 2002 Dec 16;334(3):145-8.
12 Amphetamines, new psychoactive drugs and the monoamine transporter cycle. Trends Pharmacol Sci. 2015 Jan;36(1):41-50.
13 Novel organic cation transporter 2-mediated carnitine uptake in placental choriocarcinoma (BeWo) cells. J Pharmacol Exp Ther. 2005 Jan;312(1):192-8.
14 Interaction of organic cation transporter 3 (SLC22A3) and amphetamine. J Neurochem. 2010 Jul;114(1):142-9.
15 Involvement of CYP2D6 in the in vitro metabolism of amphetamine, two N-alkylamphetamines and their 4-methoxylated derivatives. Xenobiotica. 1999 Jul;29(7):719-32.
16 Mechanistic elucidation of amphetamine metabolism by tyramine oxidase from human gut microbiota using molecular dynamics simulations. J Cell Biochem. 2019 Jan 30.
17 Inhibitory effects of anticancer drugs on dextromethorphan-O-demethylase activity in human liver microsomes. Cancer Chemother Pharmacol. 1993;32(6):491-5.
18 Effect of genetic polymorphism on the metabolism of endogenous neuroactive substances, progesterone and p-tyramine, catalyzed by CYP2D6. Brain Res Mol Brain Res. 2004 Oct 22;129(1-2):117-23.
19 CYP2D6 polymorphisms and tamoxifen metabolism: clinical relevance. Curr Oncol Rep. 2010 Jan;12(1):7-15.
20 Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
21 Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
22 Inhibition of cytochrome P450 2D6: structure-activity studies using a series of quinidine and quinine analogues. Chem Res Toxicol. 2003 Apr;16(4):450-9.
23 Effects of propofol on human hepatic microsomal cytochrome P450 activities. Xenobiotica. 1998 Sep;28(9):845-53.
24 Pharmacogenetics of schizophrenia. Am J Med Genet. 2000 Spring;97(1):98-106.
25 Roles of CYP2A6 and CYP2B6 in nicotine C-oxidation by human liver microsomes. Arch Toxicol. 1999 Mar;73(2):65-70.
26 Structure-activity relationship for human cytochrome P450 substrates and inhibitors. Drug Metab Rev. 2002 Feb-May;34(1-2):69-82.
27 Influx Transport of Cationic Drug at the Blood-Retinal Barrier: Impact on the Retinal Delivery of Neuroprotectants. Biol Pharm Bull. 2017;40(8):1139-1145.
28 Differential pharmacological in vitro properties of organic cation transporters and regional distribution in rat brain. Neuropharmacology. 2006 Jun;50(8):941-52.
29 Expression of organic cation transporters OCT1 (SLC22A1) and OCT3 (SLC22A3) is affected by genetic factors and cholestasis in human liver. Hepatology. 2009 Oct;50(4):1227-40.
30 Multiple SLC and ABC Transporters Contribute to the Placental Transfer of Entecavir. Drug Metab Dispos. 2017 Mar;45(3):269-278.
31 Organic cation transporters: physiology, toxicology and special focus on ethidium as a novel substrate. Curr Drug Metab. 2009 Jul;10(6):617-31.
32 Organic cation transporter 3 (Slc22a3) is implicated in salt-intake regulation. J Neurosci. 2004 Mar 17;24(11):2846-51.
33 Drug specificity and intestinal membrane localization of human organic cation transporters (OCT). Biochem Pharmacol. 2005 Dec 5;70(12):1851-60.
34 Genetic variations of the SLC22A5 gene in the Chinese and Indian populations of Singapore. Drug Metab Pharmacokinet. 2010;25(1):112-9.
35 Na(+)-dependent carnitine transport by organic cation transporter (OCTN2): its pharmacological and toxicological relevance. J Pharmacol Exp Ther. 1999 Nov;291(2):778-84.
36 Colistin is substrate of the carnitine/organic cation transporter 2 (OCTN2, SLC22A5). Drug Metab Dispos. 2017 Dec;45(12):1240-1244.
37 Mutations affecting GABAergic signaling in seizures and epilepsy. Pflugers Arch. 2010 Jul;460(2):505-23.
38 Transport of ipratropium, an anti-chronic obstructive pulmonary disease drug, is mediated by organic cation/carnitine transporters in human bronchial epithelial cells: implications for carrier-mediated pulmonary absorption. Mol Pharm. 2010 Feb 1;7(1):187-95.
39 Genetic deficiency of carnitine/organic cation transporter 2 (slc22a5) is associated with altered tissue distribution of its substrate pyrilamine in mice. Biopharm Drug Dispos. 2009 Dec;30(9):495-507.
40 Cloning and functional characterization of a novel up-regulator, cartregulin, of carnitine transporter, OCTN2. Arch Biochem Biophys. 2006 Aug 1;452(1):29-37.
41 Chronic depolarization stimulates norepinephrine transporter expression via catecholamines. J Neurochem. 2006 May;97(4):1044-51.
42 Characterization of VNTRs Within the Entire Region of SLC6A3 and Its Association with Hypertension. DNA Cell Biol. 2017 Mar;36(3):227-236.
43 Brexpiprazole reduces hyperactivity, impulsivity, and risk-preference behavior in mice with dopamine transporter knockdown-a model of mania. Psychopharmacology (Berl). 2017 Mar;234(6):1017-1028.
44 Which form of dopamine is the substrate for the human dopamine transporter: the cationic or the uncharged species? J Biol Chem. 1999 Feb 19;274(8):4876-82.
45 Pharmacological characterization of a dopamine transporter ligand that functions as a cocaine antagonist. J Pharmacol Exp Ther. 2014 Jan;348(1):106-15.
46 2007 FDA drug approvals: a year of flux. Nat Rev Drug Discov. 2008 Feb;7(2):107-9.
47 Diagnostic pharmacology of the pupil.Clin Neuropharmacol.1985;8(1):27-37.
48 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
49 Clinical pipeline report, company report or official report of Roche.
50 Differential modulation of Beta-adrenergic receptor signaling by trace amine-associated receptor 1 agonists. PLoS One. 2011;6(10):e27073.
51 The selective antagonist EPPTB reveals TAAR1-mediated regulatory mechanisms in dopaminergic neurons of the mesolimbic system. Proc Natl Acad Sci U S A. 2009 Nov 24;106(47):20081-6.
52 The Trace Amine 1 receptor knockout mouse: an animal model with relevance to schizophrenia. Genes Brain Behav. 2007 Oct;6(7):628-39.
53 Anggard E, Jonsson LE, Hogmark AL, Gunne LM "Amphetamine metabolism in amphetamine psychosis." Clin Pharmacol Ther 14 (1973): 870-80. [PMID: 4729903]
54 Ban TA "Drug interactions with psychoactive drugs." Dis Nerv Syst 36 (1975): 164-6. [PMID: 1116424]
55 Product Information. Ranexa (ranolazine). Calmoseptine Inc, Huntington Beach, CA.
56 Product Information. Multaq (dronedarone). sanofi-aventis , Bridgewater, NJ.
57 Product Information. Onfi (clobazam). Lundbeck Inc, Deerfield, IL.
58 Achor MB, Extein I "Diet aids, mania, and affective illness" Am J Psychiatry 138 (1981): 392. [PMID: 7468847]
59 Product Information. Northera (droxidopa). Chelsea Therapeutics Inc, Charlotte, NC.
60 Product Information. Adderall XR (amphetamine-dextroamphetamine). Shire Richwood Pharmaceutical Company Inc, Florence, KY.
61 Cerner Multum, Inc. "Australian Product Information.".
62 Product Information. Myrbetriq (mirabegron). Astellas Pharma US, Inc, Deerfield, IL.
63 Product Information. Enablex (darifenacin). Novartis Pharmaceuticals, East Hanover, NJ.
64 AbdelRahman SM, Gotschall RR, Kauffman RE, Leeder JS, Kearns GL "Investigation of terbinafine as a CYP2D6 inhibitor in vivo." Clin Pharmacol Ther 65 (1999): 465-72. [PMID: 10340911]
65 Product Information. Rescriptor (delavirdine). Pharmacia and Upjohn, Kalamazoo, MI.
66 Product Information. Stribild (cobicistat/elvitegravir/emtricitabine/tenofov). Gilead Sciences, Foster City, CA.
67 Product Information. Adderall (amphetamine-dextroamphetamine) Shire Richwood Pharmaceutical Company, Florence, KY.
68 Product Information. Norvir (ritonavir). Abbott Pharmaceutical, Abbott Park, IL.
69 Product Information. Givlaari (givosiran). Alnylam Pharmaceuticals, Cambridge, MA.
70 Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates). Braintree Laboratories, Braintree, MA.
71 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
72 Product Information. Vizimpro (dacomitinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
73 Product Information. Zelboraf (vemurafenib). Genentech, South San Francisco, CA.
74 Product Information. Tasigna (nilotinib). Novartis Pharmaceuticals, East Hanover, NJ.
75 Product Information. Gleevec (imatinib mesylate). Novartis Pharmaceuticals, East Hanover, NJ.
76 Product Information. Varubi (rolapitant). Tesaro Inc., Waltham, MA.
77 Canadian Pharmacists Association.
78 Product Information. Belviq (lorcaserin). Eisai Inc, Teaneck, NJ.
79 Product Information. Ultram (tramadol). McNeil Pharmaceutical, Raritan, NJ.
80 Matsuoka LY "Convulsions following application of gamma benzene hexachloride." J Am Acad Dermatol 5 (1981): 98-9. [PMID: 6168673]
81 Product Information. Zytiga (abiraterone). Centocor Inc, Malvern, PA.
82 Product Information. Celebrex (celecoxib). Searle, Chicago, IL.
83 Lake CR "Manic psychosis after coffee and phenylpropanolamine." Biol Psychiatry 30 (1991): 401-4. [PMID: 1912131]